US-based clinical-stage biotechnology company RadioMedix has collaborated with AREVA Med to begin a Phase l trial of 212Pb-AR-RMX (AlphaMedix) to treat patients with somatostatin receptor positive neuroendocrine tumours (NETs).
The open-label, dose escalation study seeks to evaluate safety, bio-distribution, and preliminary effectiveness of AlphaMedixin adult patients with differentiated NETs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AlphaMedix is a combination of a somatostatin (SST) analogue radiolabeled with 212Pb isotope that is used for targeted alpha-emitter therapy (TAT).
The trial is set to enrol patients at Excel Diagnostic and Nuclear Oncology Center in Houston, Texas, US.
RadioMedix chairman and CEO Dr Ebrahim Delpassand said: “Targeted alpha-emitter therapy (TAT) is the wave of the future in nuclear oncology and has a tremendous potential to treat patients with NET and overcome some of the limitations of current peptide receptor radionuclide therapy (PRRT).”
NETs are a mixed group of rare neoplasms that originate from neuroendocrine cells and occur primarily in the gastrointestinal tract and pancreas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe situation can also occur in other tissues such as thymus, lung, and other uncommon sites including ovaries, heart, and prostate.
Most of the NETs strongly demonstrate somatostatin receptors (SSTRs).
In June last year, RadioMedix and AREVA Med concluded an exploratory clinical trial that examined the biodistribution and safety of 203Pb-AR-RMX in patients with somatostatin receptor positive NETs.
